Since the beginning of this year, many pharmaceutical companies have chosen to shrink their pipelines to withdraw funds and concentrate resources on projects with higher success rates
.
In October, Harbour Biomed announced that it had terminated its Phase III clinical trial of tenarcept (HBM9036) and would no longer enroll new subjects.
At the same time, it sold its interests in bartolimab (HBM9161) in Greater China to CSPC for
1 billion yuan.
In August, Genting Sun Yao announced that the company and its wholly-owned subsidiaries, Everest Medicines II and Everest SG, had signed termination and transition service agreements
with Immunomedics, a wholly-owned subsidiary of Gilead.
On June 13, Watson Biologics announced that the recombinant EV71 vaccine is mainly used to prevent hand, foot and mouth disease
caused by EV71 virus infection.
Due to the gradual reduction of the economic and social benefits of the product, and the market competition of the product will be fierce in the future, the company and Shanghai Zerun decided to terminate the clinical research of
recombinant EV71 vaccine.
According to the company's overall product strategy, Shanghai Zerun, a subsidiary, will concentrate its superior resources to fully promote the bivalent HPV vaccine WHOPQ prequalification, 9-valent HPV vaccine clinical research, and recombinant new crown vaccine clinical research at home and abroad
.
On June 5, Clover announced that in order to fully promote the successful launch of the new crown vaccine, it suspended the continued investment in one tumor project and two biosimilar projects, namely SCB-313 (TRAIL-trimer tumor product), SCB-808 and SCB-420 (Fc fusion protein project).
Among them, SCB-313 (TRAIL-trimer tumor product) is a research project of Clover's tumor pipeline, and its indications include malignant ascites (MA), malignant pleural effusion (MPE) and peritoneal cancer (PC), all of which are in clinical phase I
.
In May, several media reported that the international phase III clinical trial of Green Valley Pharmaceutical's Alzheimer's disease (AD) drug GV-971 (mannut sodium capsule, trade name: phase IX I) had been stopped
.
Phase 9 I was conditionally approved by the NMPA in November 2019 for mild to moderate Alzheimer's disease (AD) and improved cognitive function
in patients.
In December 2021, Phase 9 was included in the medical insurance catalogue, and the price dropped by more than 60%.
However, due to clinical data problems, which have aroused many doubts, Green Valley Pharmaceutical previously announced its intention to invest 3 billion US dollars to support real-world research after Phase IX and Phase 1 marketing, international multi-center phase 3 clinical research "green memory", expand indications and mechanism in-depth research
.
In addition, Zai Lab disclosed in its 2022 half-year report that the company suspended the clinical trial of two new drugs to improve the efficiency
of capital utilization.
Hengrui also mentioned on the call that some clinical projects need to be suspended
after the disclosure of this year's interim report.
In the eyes of the industry, innovative drugs have the characteristics of long research and development time, large investment and high operating costs, especially the research and development of biological innovative original drugs is very difficult, and it may take more than ten years to develop, with an investment of more than 1 billion US dollars, and it is difficult to succeed
.
In the process of innovative drug research and development, in addition to R&D funds, it also needs R&D talents, R&D space, software and hardware and other aspects of resource guarantee, for some new drug pipelines with poor clinical effects, unclear market prospects, and insufficient investment strength, it is reasonable for pharmaceutical companies to endure pain and love early, and by shrinking the pipeline, resources can be concentrated on more
confident projects.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
